RE:RE:RE:RE:Encouraging You know I'm not a science guy up here, but my limited understanding is that if you think about how to stop tumor growth, oncology drugs have been about killing tumor cells so they no longer proliferate and it shrinks. First you had toxins with no targeting, then targeting came along and you attached toxins, then radionucleoid, and now bits of RNA that disrupt the intracellular mechanism's genetically. That's my super big picture, generalist understanding. And siRNA is the latter category, actually getting a bit of RNA in the cell to destroy or distrupt the tumor cells genetic code. I am sure the science guys here can explain this far better.
palinc2000 wrote: Can you elaborate how that would be different from the current PDC ?
qwerty22 wrote: Here is an example of an siRNA conjugate developed by academic researchers at Duke that delivers siRNA to prostate cancer by targeting the PSMA antigen.
https://www.qpcrupdate.info/mcnamara-sirna-2006.pdf
qwerty22 wrote:
Seems exciting. I would generally think of this as the expansion of the SORT1 technology that would come after validation of TH1902 in the present trial. After all if they have nothing coming out of this trial it's much harder to get the investment in follow on molecules. Having said that, in the scheme of things, it's a pretty small investment in one scientist and bench fees. So again it looks like they believe that the validation is coming (maybe).